Search results
- Regulatory news (469) Apply Regulatory news filter
- Press releases (241) Apply Press releases filter
- Basic page (60) Apply Basic page filter
- Corporate presentations (28) Apply Corporate presentations filter
- Pipeline (26) Apply Pipeline filter
- Shareholder meeting (24) Apply Shareholder meeting filter
- Team member (22) Apply Team member filter
- Videos (16) Apply Videos filter
- Financial reports (13) Apply Financial reports filter
- Webcasts and audio (13) Apply Webcasts and audio filter
- Analyst (12) Apply Analyst filter
- Event (7) Apply Event filter
- Investor contact (5) Apply Investor contact filter
- Research (3) Apply Research filter
- Financial calendar (1) Apply Financial calendar filter
- Webform (1) Apply Webform filter
Balancing risk to optimise reward
Oxford BioMedica is a leader in lentivirus based gene technology and ongoing manufacturing deals (CTL019 with Novartis) underpin the valuation.
Harnessing the CAR-T
Over the past year, Oxford BioMedica’s outlook has been transformed.
New non-dilutive funding to expand production
Oxford BioMedica has secured a $50m loan facility from Oberland Capital.
Company Secretary and Registered Office
Natalie Walter
Oxford Biomedica plc
Windrush Court
Transport Way
Oxford
OX4 6LT
United Kingdom
Corporate Brokers
Peel Hunt LLP (Corporate Brokers):
James Steel
Christopher Golden
Tel: +44 (0)20 7418 8900